Targeting FGFR

  • Fibroblast growth factor (FGF) receptors (FGFR1, FGFR2, FGFR3, and FGFR4) are receptor tyrosine kinases involved in cell proliferation, cell differentiation, cell migration, and cell survival1
  • FGFR genetic alterations have been implicated as oncogenic drivers in a variety of tumor types. Some examples of these genetic alterations are FGFR gene amplifications, activating mutations, and chromosomal translocations2,3
  • Therapeutic targeting of FGFRs implicated in oncogenesis is a major area of drug development research4

Learn about FGFRs

QED Pipeline

Clinical Trials Currently Enrolling*


An observational research study designed to learn more about the overall health, growth, and possible medical complications in children with achondroplasia (a bone growth disorder). No medication will be administered; however, children successfully enrolled in PROPEL for 6 months or more may be eligible for subsequent treatment trials sponsored by QED Therapeutics, including PROPEL 2.


  1. Touat M et al. Clin Cancer Res. 2015;21(12):2684-2694.
  2. Turner N et al. Nat Rev Cancer. 2010;10:116-129.
  3. Katoh M. Nat Rev Clin Oncol. 2019;16:105-122.
  4. Babina IS et al. Nat Rev Cancer. 2017;17:318-332.
  5. TRUSELTIQ Prescribing Information. Brisbane, CA: QED Therapeutics, Inc.; [Month] 2021.
  6. American Cancer Society. Accessed March 27, 2021.
  7. Lamarca A et al. J Clin Med. 2020;9(9):2854.
  8. Arai Y et al. Hepatology. 2014;59(4):1427-1434.
  9. Kongpetch S et al. JCO Global Oncol. 2020;6:628-638.
  1. Ross JS et al. Cancer. 2016;122(5):702-711.
  2. Sfakianos JP et al. Eur Urol. 2015;68(6):970-977.
  3. Moss TJ et al. Eur Urol. 2017;72(4):641-649.
  4. Bagrodia A et al. J Urol. 2016;195(6):1684-1689.
  5. Bagrodia A et al. Eur Urol Focus. 2019;5(3):365-368.
  6. Audenet F et al. Clin Cancer Res. 2019;25(3):967-976.
  7. Komla-Ebri D et al. J Clin Invest. 2016;126(5):1871-1884.
  8. National Institutes of Health. Accessed April 1, 2021.
  9. Legare JM et al. Accessed April 1, 2021.